Study #2023-1032
A phase 2, randomized, open-label study of Onvansertib in combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for first-line treatment of metastatic colorectal cancer in patients with a KRAS or NRAS mutation
MD Anderson Study Status
Enrolling
Treatment Agent
Onvansertib, FOLFIRI, Bevacizumab, FOLFOX
Description
The purpose of this study is to assess 2 different doses of onvansertib to select the lowest dose that is maximally effective, and to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of onvansertib in combination with FOLFIRI + bevacizumab or FOLFOX + bevacizumab in patients with KRAS or NRAS-mutated metastatic colorectal cancer (CRC) in the first-line setting.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation
Study phase:
Phase II
Physician name:
Alisha Bent
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-855-401-1031
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.